Rapid MLS

by RapidAI  · Based in United States → — Clinical AI Platform Enhancing Assessment & Care
Neurology Neurosurgery Radiology

Regulatory Status Disclosed

Overview

Rapid MLS, developed by iSchemaview (operating as RapidAI), is an AI-powered software designed to analyze non-contrast CT (NCCT) scans. It accurately measures and visually displays brain midline shifts, providing quantitative data and annotated images to assist clinicians. This tool supports the assessment of critical neurological conditions such as intracranial hemorrhage and traumatic brain injury, aiding in faster and more informed clinical decision-making. Rapid MLS utilizes advanced machine learning algorithms to process DICOM format images and delivers results in annotated images and JSON reports. It is an integral part of the broader RapidAI platform, which offers a comprehensive suite of AI-driven solutions for cerebrovascular imaging and stroke care, including modules for ICH, ASPECTS, CTA, LVO, and HVS. The platform integrates with existing hospital systems like PACS and EMR, and provides real-time alerts and collaboration features via a mobile app, enhancing communication and workflow efficiency for stroke teams globally.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered analysis of non-contrast CT scans
  • Measures and visually displays brain midline shifts
  • Provides quantitative measurements and annotated images
  • Supports assessment of intracranial hemorrhage and traumatic brain injury
  • Utilizes machine learning algorithms for image analysis
  • Processes DICOM format images
  • Outputs JSON reports with quantitative measurements
  • Integration with PACS, email, and mobile app for result dissemination
  • Real-time alerts and notifications for urgent cases
  • In-app messaging for team collaboration
  • EMR integration for patient case summaries
  • Advanced 3D imaging reconstruction (for broader RapidAI platform)

Use Cases

  • Assessing intracranial hemorrhage
  • Assessing traumatic brain injury
  • Triage and decision-making in acute neurological emergencies
  • Quantifying mass effect and herniation risk
  • Expediting diagnosis in neurovascular cases
  • Streamlining treatment decisions for stroke patients

What Physicians Need to Know

Stroke Detection Speed
RapidAI's platform can process scans in under two minutes. Rapid LVO can detect anterior circulation large vessel occlusions in a mean average time of 3 minutes 30 seconds. Rapid ICH can notify clinicians of suspected intracranial hemorrhage cases within three minutes of receiving the case.
Brain MRI/CT Analysis
RapidAI's platform uses AI to create high-quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The platform includes modules for NCCT Stroke, ASPECTS, Hypodensity, Rapid LMVO, Rapid CTA, Perfusion Imaging, and AngioFlow. Rapid MLS detects and quantifies suspected midline shift, a key indicator of brain injury, with a mean absolute error of just 0.8 mm. Rapid OH identifies suspected obstructive hydrocephalus by detecting cerebrospinal fluid accumulation in the lateral ventricles and generates alerts.
Large Vessel Occlusion Detection
Rapid LVO can quickly detect anterior circulation large vessel occlusions with high sensitivity (96%) and specificity (98%). Rapid LMVO detects suspected vessel occlusions in the ICA, MCA, ACA, Basilar, and PCA, and has been shown to triage 27% more patients compared to Rapid LVO. RapidAI's platform has demonstrated higher sensitivity in detecting LVOs compared to other AI software, identifying 98% of LVOs in a comparative study.
Triage Prioritization Speed
Rapid ICH uses AI to speed up the triage of NCCT and notify clinicians of suspected ICH cases within three minutes. The RapidAI app can flag suspected large vessel blockages within 5 minutes after CT scanning and sends alerts and images to all connected team members. Reduced time to treatment was reported for Rapid CTA (by 25 minutes) and Rapid CTP (by 36 minutes), and reduced turnaround times for CT reports for Rapid LVO (by nine minutes).
ASPECTS Score Automation
Rapid ASPECTS uses a machine learning algorithm for automatic identification of the Alberta Stroke Program Early CT Score (ASPECTS) regions of the brain to generate an ASPECT score. It provides an automated system for scoring non-contrast CT scans in the presence of LVO. Studies have shown that Rapid ASPECTS assistance improves the accuracy and uniformity of ASPECT scores, particularly for non-neuroradiologists, and can increase overall accuracy from 0.72 to 0.82.
Mobile Notification System
Clinicians are notified of suspected ICH and LVO cases via a mobile application. Results are instantly delivered to the care team through the mobile app, PACS, and integrated systems. The RapidAI app prepares and alerts neurological staff working on patients with ischemic stroke, allowing for rapid and simultaneous communication among team members.
Physician Tip

RapidAI's suite of tools can significantly expedite stroke diagnosis and treatment workflows. Leverage the mobile notification system for real-time alerts and improved team communication, which can shave minutes off response times. Utilize the automated ASPECTS scoring to enhance consistency and accuracy in evaluating non-contrast CT scans, especially in settings where neuroradiology expertise may not be immediately available. The detailed imaging analysis for LVO and ICH detection can aid in quicker decision-making for thrombectomy eligibility and patient transfer. Remember that while AI tools provide rapid and accurate analysis, clinical judgment and review remain essential.

The RapidAI platform is designed for integration with existing hospital systems, including PACS. It offers a comprehensive AI platform for acute stroke care, with various modules for different imaging modalities and analyses. The platform also supports real-time collaboration among care teams.

Details

Category Neurology AI, Radiology & Imaging AI
Pricing Unknown
DeploymentEnterprise infrastructure, fits into existing stack with secure, vendor-agnostic integration.
Training Yes
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Neurology, Neurosurgery, Radiology

Support & Reliability

Training Provided Yes

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2025-05-28K243378 510(k)Rapid MLS

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Rapid MLS

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Rapid MLS.

View all on YouTube

Frequently Asked Questions

Rapid MLS is an AI-powered imaging module developed by RapidAI that detects and quantifies suspected midline shift, a key indicator of brain injury. It provides objective visualization with a mean absolute error of just 0.8 mm, helping clinicians identify meaningful shifts earlier. This module is part of the Rapid Enterprise Platform, which offers a comprehensive suite of AI-driven solutions for neurovascular conditions.
Yes, Rapid MLS has received U.S. Food and Drug Administration (FDA) clearance. When using AI tools like Rapid MLS, physicians must ensure compliance with evolving regulatory and privacy requirements, including HIPAA, especially when processing Protected Health Information.
While Rapid MLS offers objective measurements for midline shift, AI in general for neurological diagnosis and treatment has limitations. Traditional diagnostic AI operates on fixed, validated algorithms for specific tasks, but generative AI, which is a newer technology, may hallucinate content or lack patient-specific details. The nuanced clinical judgments, especially in complex neurology cases, still depend on human expertise. Additionally, AI tools can stumble over slurred speech, uncommon names, or rare terms, and may interpret rather than accurately summarize.
Rapid MLS is integrated into the Rapid Edge Cloud IT platform and is designed to work across PACS, EHR, and reporting systems. It also integrates with the Rapid mobile and web applications, allowing for real-time collaboration and alerts. This integration helps reduce delays, improve alignment among care teams, and accelerate time to treatment by providing rapid analysis and notifications.
Yes, there are other AI tools for neuroimaging analysis, particularly in stroke and emergency triage, such as Viz.ai. Other AI solutions in neurology include tools for EEG analysis, robotic-assisted surgery, remote monitoring, and clinical decision support systems like MedLink AI and OpenEvidence.
Pricing for clinical AI solutions in healthcare can vary significantly. Some models include free tiers, while others involve published subscriptions or enterprise contracts. Enterprise ambient documentation contracts are frequently cited between $200 and $600 per clinician per month. Pricing often depends on factors like integration quality, regulatory compliance, and the depth of clinical workflow support. Some platforms may charge per minute or per call for conversational AI, with additional fees for phone infrastructure, speech processing, and EHR integration.

Related Tools

syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
Neurophet AQUA AD Plus
Neurophet
Neurology AI
Neurophet AQUA AD Plus is an AI-powered brain imaging analysis software that supports the diagnosis, treatment guidance, and monitoring of Alzheimer's disease by analyzing MRI and PET scans.
myosmart trial kit
Otto Bock Healthcare Products GmbH
Neurology AI
The Ottobock MyoSmart Trial Kit assists clinicians in assessing and fitting advanced neurorehabilitation prosthetic and orthotic solutions.
connectgrip. (560X27-1)
Otto Bock Healthcare Products GmbH
Neurology AI
Otto Bock Healthcare Products GmbH offers advanced prosthetic and orthotic solutions, with 'connectgrip' (560X27-1) likely being a component designed for secure and functional connection within these systems, potentially incorporating intelligent features for enhanced user control.
myosmart.cuff (757M20-2)
Otto Bock Healthcare Products GmbH
Lab & Diagnostics
The myosmart.cuff is a medical device by Otto Bock Healthcare Products GmbH designed for objective measurement of muscle tone, primarily for use in neurological rehabilitation.
myosmart. (13E522)
Otto Bock Healthcare Products GmbH
Neurology AI
myosmart.

See all Neurology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-08 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.